Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial
(MoCHA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing if continuing caffeine treatment helps moderately preterm infants who had breathing issues recover faster and spend less time in the hospital. Caffeine citrate, a form of caffeine, is used to stimulate their breathing. Caffeine citrate is widely used in neonatology for treating apnea in preterm infants due to its efficacy and safety.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it does mention that participants should be receiving caffeine treatment or have just stopped it. It seems like the focus is on caffeine treatment, so other medications might not be affected.
Is caffeine citrate safe for use in humans?
Who Is on the Research Team?
Waldemar Carlo, MD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive caffeine citrate or placebo daily in the hospital, starting within 72 hours of open label caffeine discontinuation
Home Treatment
Infants continue on the same dose of caffeine citrate or placebo at home for the first 28 days after hospital discharge
Follow-up
Participants are monitored for safety and effectiveness after treatment, with biweekly contact during weeks 5 to 8 post-discharge
What Are the Treatments Tested in This Trial?
Interventions
- Caffeine Citrate
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
NICHD Neonatal Research Network
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator